DSGN Stock Forecast: Design Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$9.02
−3.22% on the day

The 8 Wall Street analysts covering Design Therapeutics, Inc. hold a median 12-month price target of $21 — +132.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$577.6M
Ticker Nerd rank
53/ 100
Median analyst target
$21
Analysts covering
8
Revenue$0.0
Operating income−$22.2M
Net income−$20.2M
Free cash flow−$15.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.8%
1M
−18.7%
YTD
−3.8%
1Y
+14.6%
From 52W high
−43.4%
From 52W low
+14.6%
$8
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Design Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
53/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
81
Accruals
65
Value
62
Volatility
56
Growth
51
Quality
48
Revisions
37
Issuance
32

Momentum (81): The shares have been drifting up relative to others.

Issuance (32): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DSGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DSGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25Jan 26Apr 26Jul 26Oct 26DSGNHigh $26Median $21Low $19

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8
Buy
0
Hold
0
Sell
$19
Low
$21
Median
$26
High

The green dot is the last close — the median target sits +132.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Nov 2026RBC CapitalMaintainsOutperform$20 → $19
2 Oct 2026Wells FargoInitiatesOverweight$26
4 May 2026OppenheimerMaintainsOutperform$18 → $21
16 Mar 2026JefferiesInitiatesBuy—
10 Mar 2026RBC CapitalMaintainsOutperform—
7 Jan 2026OppenheimerInitiatesOutperform—
3 Dec 2025Leerink PartnersUpgradeOutperform—
20 Nov 2025RBC CapitalUpgradeOutperform—
6 Nov 2025RBC CapitalMaintainsSector Perform—
6 Aug 2024RBC CapitalReiteratesSector Perform—
7 May 2024Piper SandlerUpgradeOverweight—
20 Mar 2024RBC CapitalReiteratesSector Perform—
20 Mar 2024WedbushReiteratesNeutral—
14 Nov 2023RBC CapitalMaintainsSector Perform—
15 Aug 2023RBC CapitalDowngradeSector Perform—
15 Aug 2023SVB LeerinkDowngradeMarket Perform—
15 Aug 2023WedbushDowngradeNeutral—
10 May 2023RBC CapitalMaintainsOutperform—
10 May 2023WedbushMaintainsOutperform—
4 May 2023Goldman SachsUpgradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DSGN.

Market Radar

This page is one stock. Monday covers all of them.

DSGN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DSGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Design Therapeutics, Inc. returned +14.6% against +6.9% for the S&P 500, dividends included.

DSGN vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Jan 26Apr 26Jul 26Oct 26DSGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DSGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.8×

Cheaper than 32% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−36.9%

Higher than 25% of US stocks

Return on assets
−23.9%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Design Therapeutics, Inc. has a market value of $577.6M and an enterprise value of $371.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$70.8M.

  • Diluted earnings per share, trailing twelve months: −$1.18.

  • Free cash flow in the twelve months to 30 June 2026: −$55.1M.

  • Shares outstanding: 62.6M.

  • Design Therapeutics, Inc. employs 60 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

DSGN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DSGNDesign Therapeutics, Inc.$577.6M53
GERNGeron Corp.$557.7M71
BCAXBicara Therapeutics, Inc.$552.5M24
FDMT4D Molecular Therapeutics, Inc.$565.1M50
SRZNSurrozen, Inc.$542.5M62
QUITAchieve Life Sciences, Inc.$572.1M44
ENTXEntera Bio Ltd.$572.2M38

Take a look at DSGN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Design Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about DSGN

What is the DSGN stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Design Therapeutics, Inc. have a median 12-month price target of $21, with estimates ranging from $19 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DSGN stock a buy right now?

Of the 8 analysts covering Design Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Design Therapeutics, Inc. 53 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DSGN?

As at 21 Nov 2026, Design Therapeutics, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (81 of 100).

Will DSGN stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +132.8% from the last close, and Ticker Nerd's factor model ranks Design Therapeutics, Inc. 53 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DSGN stock forecast for 2030?

No analyst covering Design Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DSGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $26 over the next 12 months.

How has DSGN stock performed over the past year?

Design Therapeutics, Inc. returned +14.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Design Therapeutics, Inc. do?

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing GeneTAC small-molecule therapies for serious genetic diseases. The company’s current programs target inherited disorders driven by nucleotide repeat expansion mutations, with a portfolio that includes treatments in development for Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington’s disease.

Company

About Design Therapeutics, Inc.

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing GeneTAC small-molecule therapies for serious genetic diseases. The company’s current programs target inherited disorders driven by nucleotide repeat expansion mutations, with a portfolio that includes treatments in development for Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington’s disease. Its approach centers on designing therapeutic candidates that act on the underlying genetic cause of disease rather than only addressing symptoms. Design Therapeutics serves the biotechnology and drug-development market through its proprietary platform, which supports research, preclinical work, and clinical development of novel medicines for patients with high unmet medical needs. The company is headquartered in Carlsbad, California.

CEO Mr. Pratik Shah Ph.D. · 60 employees · United States · https://www.designtx.com